Why invest in genome revolution?
To solve world hunger
It may be one of the most important revolutions in the history of mankind. It will make it possible to edit the genome, creating possible cures for chronic diseases. But it could also change agriculture completely, which could solve the world’s hunger problems.
The detection of genetic diseases
The human genome was first sequenced in 2003. It took 10 years and cost $30 billion USD. Now it can be sequenced for as little as $200 USD and in just a few hours. If things continue at this pace, shortly it could be done at an affordable price in a few minutes. It can be used for everything from personalised diets tailored to your DNA, improvements in physical performance and the detection of genetic diseases before they even begin to manifest themselves.
To enable more effective treatments
New life-saving therapies enable better treatments for cancer and other diseases, as well as early detection. It can multiply by a factor of 3 the life expectancy of people with cancer.
How do we invest in genome revolution?
We have selected the most relevant companies and investment vehicles worldwide to invest in the genome revolution:
Una acción representa una parte alícuota del capital social de una empresa. El comprador se convierte en socio de la empresa, en el porcentaje acorde al número de acciones compradas.
Los ETFs (Exchange Trade Funds) son un tipo de fondo de inversión, que cotiza diariamente en el mercado y que generalmente tratan de replicar un índice bursátil, por ejemplo de un país o de un sector.
Un fondo de inversión es un vehículo de inversión que aglutina las aportaciones de distintos inversores para invertirlos en una cesta de empresas u otros activos.
|Name||ISIN||Market||Currency||CCY Hedged||Download||Go to....|
Legal disclaimer & warnings
The information contained herein is only provided for informative purposes, and it does not constitute an offer, invitation or incitement to sell, buy or subscribe shares, nor should it be
interpreted as such. For legal reasons, in some states this information cannot be divulged to persons with nationality or legal residence in a state where the admission of the products
described herein is limited. The prices of the products described herein may rise or fall. References to past returns do not presuppose, predispose or condition returns in the future.
The return does not take account of the fees and rates charged when buying and selling the investment. The return from a particular portfolio may differ from that of the aggregate for numerous reasons, therefore said returns are stated merely for guidance and are under no way a guarantee of the return to be attained. Likewise, past returns do not assure future returns. Further information will be provided upon request. As compensation for its services or for other motives, BBVA SA may receive one-off or repeated remunerations (for example, issue premiums or placement fees). In certain circumstances the interests of BBVA SA may enter into conflict with those of the investor. Please contact your Investment Advisor for further information.
The publication or distribution of all or part of this documentation is prohibited unless prior written authorisation is granted by BBVA SA. Furthermore, certain information herein is based on or derives from information that is generally available to the public at large and from sources we consider to be reliable; however, no guarantee is offered with regard to its exactness. The sale of some of the investments in the portfolio may be restricted in the United States or to citizens from that country. This information cannot be sent, taken to or distributed in the United States nor can it be supplied to any person from the USA. It does not constitute a public securities offering, controlled, supervised or regulated by Central Banks, Authorities or Regulators from certain overseas countries, such as the United Kingdom, Peru, Turkey, El Salvador, Uruguay, Paraguay or Costa Rica.
News about genome revolution
At New Gen it is possible to invest in cancer research, which can help multiply by a factor of 3 the life expectancy of people suffering from this and other chronic degenerative diseases.
Today, thanks to technological progress, greater globalization of the economy and new interests in the field of medicine, a genome sequence can be obtained for almost ten million times less money.
Technological advances have taken research into the human genome to a new level where it is claimed that the cat genome is more similar to that of humans and can make a difference by becoming the key to preventing and curing diseases.
Nowadays, people can order genetic tests and find out about their vulnerability to certain diseases by sending samples by mail, and more and more companies are making great strides in the field of human genomics.
Knowledge of the human genome makes it possible to understand diseases that have a genetic basis, such as cancer, diabetes, Alzheimer's disease and cardiovascular diseases.